JP2019512693A5 - - Google Patents

Download PDF

Info

Publication number
JP2019512693A5
JP2019512693A5 JP2018548001A JP2018548001A JP2019512693A5 JP 2019512693 A5 JP2019512693 A5 JP 2019512693A5 JP 2018548001 A JP2018548001 A JP 2018548001A JP 2018548001 A JP2018548001 A JP 2018548001A JP 2019512693 A5 JP2019512693 A5 JP 2019512693A5
Authority
JP
Japan
Prior art keywords
aimp2
fragment
hsp70
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018548001A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019512693A (ja
JP6914269B2 (ja
Filing date
Publication date
Priority claimed from KR1020160027077A external-priority patent/KR102297505B1/ko
Application filed filed Critical
Publication of JP2019512693A publication Critical patent/JP2019512693A/ja
Publication of JP2019512693A5 publication Critical patent/JP2019512693A5/ja
Application granted granted Critical
Publication of JP6914269B2 publication Critical patent/JP6914269B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018548001A 2016-03-07 2017-03-07 Ａｉｍｐ２−ｄｘ２とｈｓｐ７０との結合を阻害する抗がん剤スクリーニング方法 Active JP6914269B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2016-0027077 2016-03-07
KR1020160027077A KR102297505B1 (ko) 2016-03-07 2016-03-07 Aimp2-dx2와 hsp70의 결합을 저해하는 항암제 스크리닝 방법
PCT/KR2017/002442 WO2017155277A1 (ko) 2016-03-07 2017-03-07 Aimp2-dx2와 hsp70의 결합을 저해하는 항암제 스크리닝 방법

Publications (3)

Publication Number Publication Date
JP2019512693A JP2019512693A (ja) 2019-05-16
JP2019512693A5 true JP2019512693A5 (enExample) 2020-06-18
JP6914269B2 JP6914269B2 (ja) 2021-08-04

Family

ID=59790548

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018548001A Active JP6914269B2 (ja) 2016-03-07 2017-03-07 Ａｉｍｐ２−ｄｘ２とｈｓｐ７０との結合を阻害する抗がん剤スクリーニング方法

Country Status (6)

Country Link
US (1) US11442057B2 (enExample)
EP (1) EP3418739B1 (enExample)
JP (1) JP6914269B2 (enExample)
KR (1) KR102297505B1 (enExample)
CN (1) CN109073638B (enExample)
WO (1) WO2017155277A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101831435B1 (ko) * 2016-03-10 2018-02-22 재단법인 의약바이오컨버젼스연구단 Aimp2-dx2 단백질에 특이적으로 결합하는 항체
US11758948B2 (en) 2018-01-29 2023-09-19 Altria Client Services Llc Lighting unit for aerosol-generating systems
KR102745000B1 (ko) 2018-01-29 2024-12-20 필립모리스 프로덕츠 에스.에이. 에어로졸 발생 시스템용 조명 유닛
WO2019209083A1 (ko) 2018-04-26 2019-10-31 재단법인 의약바이오컨버젼스연구단 mTOR 저해제로서의 신규 화합물 및 이의 용도
EP4313113A4 (en) * 2021-03-30 2025-04-16 Board of Regents, The University of Texas System CITRULLINATED PROTEINS USED AS BIOMARKERS AND THERAPEUTIC TARGETS FOR CANCER
CN115786504B (zh) * 2022-08-31 2023-09-19 中国人民解放军总医院京南医疗区 Hspa4抑制剂在治疗黑素瘤中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8039218B2 (en) * 2002-11-14 2011-10-18 John Wayne Cancer Institute Detection of cancer cells in body fluids
US7459529B2 (en) 2004-11-24 2008-12-02 Seoul National University Industry Foundation AIMP2-DX2 and its uses
US8003780B2 (en) * 2004-11-24 2011-08-23 Neomics Co., Ltd. AIMP2-DX2 gene and SiRNA targeting AIMP2-DX2
KR20060057992A (ko) * 2004-11-24 2006-05-29 재단법인서울대학교산학협력재단 ｐ38-ＤＸ2 및 이의 용도
EP2386854A1 (en) * 2005-04-19 2011-11-16 Prediction Sciences LLC Diagnostic markers of breast cancer treatment and progression and methods of use thereof
WO2007011856A2 (en) * 2005-07-15 2007-01-25 The Trustees Of Columbia University In The City Of New York Compositions and methods for differential diagnosis of chronic lymphocytic leukemia
KR20070113926A (ko) * 2006-05-26 2007-11-29 재단법인서울대학교산학협력재단 암의 진단과 치료를 위한 ａｉｍｐ2ｄｘ2의 용도
US8754094B2 (en) * 2007-08-15 2014-06-17 The Research Foundation Of State University Of New York Methods for heat shock protein dependent cancer treatment
KR101067816B1 (ko) * 2007-11-09 2011-09-27 (주)네오믹스 Ａｉｍｐ2-ｄｘ2의 억제제를 유효성분으로 포함하는 염증성질환 예방 및 치료용 조성물
US20120178111A1 (en) * 2009-09-23 2012-07-12 Diamandis Eleftherios P Methods and compositions for the detection of lung cancers
EP2566499B1 (en) * 2010-05-04 2017-01-25 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex
WO2013006076A1 (en) * 2011-07-04 2013-01-10 New York University The use of intranasally administered hsp70 protein to treat neurodegenerative diseases
KR20130016041A (ko) * 2011-08-04 2013-02-14 재단법인 의약바이오컨버젼스연구단 신규한 아닐린 유도체 및 이의 용도
KR101500804B1 (ko) * 2012-04-20 2015-03-11 단국대학교 산학협력단 Ａｉｍｐ２ 유전자의 스플라이싱 변이체 특이적인 트랜스-스플라이싱 활성을 갖는 핵산 분자 및 이를 이용한 폐암 치료용 약학 조성물 및 폐암 진단용 조성물
KR20130118612A (ko) * 2012-04-20 2013-10-30 (주)네오믹스 신규한 아미노피리딘 유도체 및 이의 용도
KR101464360B1 (ko) * 2012-11-09 2014-11-21 주식회사 대웅 리보자임과 shRNA를 함유하는 아데노바이러스 및 이를 포함하는 암 치료용 조성물
WO2014142619A1 (ko) * 2013-03-14 2014-09-18 부산대학교산학협력단 Aimp2-dx2와 pl4/arf의 상호작용을 이용한 암 치료제의 스크리닝 방법
KR101762433B1 (ko) * 2013-06-05 2017-07-28 재단법인 의약바이오컨버젼스연구단 신규한 말레인산 유도체 및 이의 제조방법 및 이를 포함하는 항암용 조성물
KR101514320B1 (ko) * 2013-06-14 2015-04-22 재단법인 의약바이오컨버젼스연구단 신규한 암 예방 또는 치료용 약학적 조성물
KR101621963B1 (ko) * 2014-03-06 2016-05-17 한국과학기술원 Aimp2의 엑손2 결손체 돌연변이 검출용 분자신호기 및 이를 이용한 aimp2 돌연변이의 검출방법
EP3162803B1 (en) * 2014-06-30 2019-09-11 Pusan National University Industry-University Cooperation Foundation New compound for inhibiting binding between dx2 protein and p14/arf protein, and pharmaceutical composition for treating or preventing cancer disease containing same as effective ingredient

Similar Documents

Publication Publication Date Title
JP2019512693A5 (enExample)
JP2017048194A5 (enExample)
UA124343C2 (uk) Капсиди аденоасоційованого вірусу і спосіб його використання
JP2017200489A5 (enExample)
RU2021134101A (ru) Модифицированная j-цепь
JP2023082054A5 (enExample)
MX2020010806A (es) Peptidos anti-inflamatorios y usos de los mismos.
JP2009225798A5 (enExample)
JP2015038108A5 (enExample)
CN109311961A (zh) 一种索马鲁肽的合成方法
EP3936141A3 (en) Anti-senescence compounds and uses thereof
EA201792651A1 (ru) Аденовирусные полинуклеотиды и полипептиды
JP2013539454A5 (enExample)
PH12014501083A1 (en) Anticancer fusion protein
EA201390820A1 (ru) Слитый белок против рака
JP2011530309A5 (enExample)
EA201791238A1 (ru) Способы и композиции, в которых используются варианты полипептидов klotho
WO2019081595A3 (en) Dpp3 binder directed to and binding to specific dpp3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress
PL393578A1 (pl) Przeciwnowotworowe białko fuzyjne
EP4374913A3 (en) Novel human serum albumin mutant
WO2016061504A3 (en) Recombinant antibodies that recongnize the c-terminal domains of ebola virus nucleoprotein
EA201790341A1 (ru) Анти-ск8 антитела для применения в лечении рака
CN109937252A (zh) 重组dna聚合酶
JP2017505772A5 (enExample)
CU24609B1 (es) Proteína de fusión que comprende una proteína de subunidad de ferritina monomérica unida a una proteína de dominio alfa 3 de mic